CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the ...

Zanubrutinib is under clinical development by BeiGene and currently in Phase II for Unspecified B-Cell Lymphomas.

An investigational therapy is demonstrating preclinical promise against non-Hodgkin lymphoma by boosting natural killer cells ...

Micrograph of a diffuse large B cell lymphoma, AbbVie and partner Genmab have FDA approval for the lead drug in their $3.9 billion cancer partnership, with bispecific antibody Epkinly now cleared ...

Chugai Pharma receives Japanese regulatory approval for Lunsumio for intravenous infusion for relapsed/refractory follicular lymphoma: Tokyo Saturday, December 28, 2024, 13:00 Hrs ...

Researchers from Janssen Research & Development LLC presented preclinical data for JNJ-87801493, a first-in-class CD20 targeted CD28 costimulatory bispecific antibody (Ab), currently in early clinical ...